期刊
CLINICAL CANCER RESEARCH
卷 18, 期 7, 页码 1824-1826出版社
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/1078-0432.CCR-12-0151
关键词
-
类别
资金
- NIDDK NIH HHS [R01 DK076986, R01 DK076986-05] Funding Source: Medline
- ICREA Funding Source: Custom
Second-line therapies are needed for patients with advanced hepatocellular carcinoma who progress after sorafenib. Positive signals seen with brivanib in phase II studies, reported herein, have yet to be confirmed in phase III trials. Identification of the molecular mechanisms driving sorafenib resistance should guide drug development strategies in this setting. Clin Cancer Res; 18(7); 1824-6. (C) 2012 AACR.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据